ABSTRACT
For chronic hepatitis C patents with end-stage renal disease (ESRD) undergoing hemodialysis, most guidelines recommend the use of direct-acting antivirals containing protease inhibitor (PI), yet dialysis patients with severe liver injury are often unable to receive such treatment due to contraindications to PIs. This article briefly introduces the unmet treatment needs in hepatitis C patients with ESRD undergoing dialysis, reviews the data from clinical trials and real-world studies investigating the use of PI-free sofosbuvir (SOF)-based regimens in such patients, and explores the value of SOF-based regimens in the treatment of dialysis patients in China and issues requiring further research. It is pointed out that full-dose SOF-based regimens have good clinical effect, tolerability, and safety in dialysis patients and thus provide additional safe and effective treatment options for such patients with moderate or severe liver injury.